Cited by 1,557Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Open access

Ridker, Paul M., Rifai, Nader, Clearfield, Michael, Downs, John R., Weis, Stephen E., Miles, J. Shawn, Gotto, Antonio M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200106283442601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200106283442601

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citation
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952

Show all 27 references

Sorted by citations

Items 201–300 of 998

High-Sensitivity C-Reactive Protein and Coronary Heart Disease Mortality in Patients With Type 2 Diabetes
Soinio, M., Marniemi, J., Laakso, M., Lehto, S., & Rönnemaa, T. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1700 · Cited by 186
C-Reactive Protein Predicts Progression of Atherosclerosis Measured at Various Sites in the Arterial Tree
van der Meer, I. M., de Maat, M. P. M., Hak, A. E., Kiliaan, A. J., del Sol, A. I., van der Kuip, D. A. M., Nijhuis, R. L. G., Albert Hofman, D., & Witteman, J. C. M. (2002) · Stroke · doi:10.1161/01.str.0000044168.00485.02 · Cited by 186
C-reactive protein: a nontraditional serum marker of cardiovascular risk
de Ferranti, S. D., & Rifai, N. (2007) · Cardiovascular Pathology · doi:10.1016/j.carpath.2006.04.006 · Cited by 185
Self-citation
Pleiotropic effects of HMG-CoA reductase inhibitors
Werner, N., Nickenig, G., & Laufs, U. (2002) · Basic Research in Cardiology · doi:10.1007/s003950200000 · Cited by 186
The pleiotropic effects of statins
Calabrò, P., & Yeh, E. T. H. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000181482.99067.bf · Cited by 182
Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients
Descamps‐Latscha, B., Witko‐Sarsat, V., Nguyen‐Khoa, T., Nguyen, A., Gausson, V., Mothu, N., London, G. M., & Jungers, P. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.09.011 · Cited by 182
C-reactive protein and interleukin-6 in vascular disease
Rattazzi, M., Puato, M., Faggin, E., Bertipaglia, B., Zambon, A., & Pauletto, P. (2003) · Journal of Hypertension · doi:10.1097/00004872-200310000-00002 · Cited by 180
C-reactive protein: history and revival
Ablij, H. C., & Meinders, A. E. (2002) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(02)00132-2 · Cited by 175
Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with Type 2 diabetes: one-year follow-up of a randomised trial
Brinkworth, G. D., Noakes, M., Parker, B., Foster, P., & Clifton, P. M. (2004) · Diabetologia · doi:10.1007/s00125-004-1511-7 · Cited by 175
Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk
Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.082 · Cited by 186
Self-citation
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease
Biasucci, L. M. (2004) · Circulation · doi:10.1161/01.cir.0000148983.88334.80 · Cited by 174
Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
Aday, A. W., & Ridker, P. M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00016 · Cited by 178
Self-citation
Inhibition of Hydroxymethylglutaryl-Coenzyme A Reductase Reduces Th1 Development and Promotes Th2 Development
Hakamada‐Taguchi, R., Uehara, Y., Kuribayashi, K., Numabe, A., Saito, K., Negoro, H., Fujita, T., Toyo‐oka, T., & Kato, T. (2003) · Circulation Research · doi:10.1161/01.res.0000101298.76864.14 · Cited by 173
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts
Abbruzzese, T. A., Havens, J. M., Belkin, M., Donaldson, M. C., Whittemore, A. D., Liao, J. K., & Conte, M. S. (2004) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2003.12.027 · Cited by 171
Pharmacotherapy for dyslipidaemia ? current therapies and future agents
Bays, H. E., & Stein, E. A. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.1901 · Cited by 173
Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
Fonseca, V. A., Desouza, C. V., Asnani, S., & Jialal, I. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0034 · Cited by 169
Treatment of Post-Myocardial Infarction Depressive Disorder: A Randomized, Placebo-Controlled Trial With Mirtazapine
Honig, A., Kuyper, A. M. G., Schene, A. H., van Melle, J. P., de Jonge, P., Tulner, D. M., Schins, A., Crijns, H. J. G. M., Kuijpers, P. M. J. C., Vossen, H., et al. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31814b260d · Cited by 167
Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein
Kinlay, S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.083 · Cited by 164
Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial
Jonkers, I. J. A. M., Mohrschladt, M. F., Westendorp, R. G. J., van der Laarse, A., & Smelt, A. H. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01123-8 · Cited by 169
Socioeconomic Position, Race/Ethnicity, and Inflammation in the Multi-Ethnic Study of Atherosclerosis
Ranjit, N., Diez-Roux, A. V., Shea, S., Cushman, M., Ni, H., & Seeman, T. (2007) · Circulation · doi:10.1161/circulationaha.107.706226 · Cited by 168
Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein
Ridker, P. M., MacFadyen, J. G., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., et al. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.848473 · Cited by 163
Self-citation
Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden
Brevetti, G., Silvestro, A., Giacomo, S. D., Bucur, R., Donato, A. D., Schiano, V., & Scopacasa, F. (2003) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(03)00124-1 · Cited by 165
Markers of inflammation and their clinical significance
Ballantyne, C. M., & Nambi, V. (2005) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2005.02.005 · Cited by 168
C-reactive protein: a new risk assessment tool for cardiovascular disease.
Clearfield, M. B. (2005) · PubMed · Cited by 160
Self-citation
AJC Editor's Consensus: Psoriasis and Coronary Artery Disease
Friedewald, V. E., Cather, J. C., Gelfand, J. M., Gordon, K. B., Gibbons, G. H., Grundy, S. M., Jarratt, M., Krueger, J. G., Ridker, P. M., Stone, N. J., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.004 · Cited by 163
Self-citation
Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
McMurray, J. J. V., KJEKSHUS, J. K., Gullestad, L. L., Dunselman, P., Hjalmarson, Å. C., Wedel, H., Lindberg, M., Waagstein, F., Grande, P., Hradec, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.849117 · Cited by 162
Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases
Mansouri, A., Reiner, Ž., Ruscica, M., Tedeschi-Reiner, E., Radbakhsh, S., Ekta, M. B., & Sahebkar, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051313 · Cited by 173
Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders
Gao, X., Bermudez, O. I., & Tucker, K. L. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.4.913 · Cited by 158
C-reactive protein and cardiovascular disease: a review of risk prediction and interventions
de Ferranti, S. D., & Rifai, N. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00797-5 · Cited by 162
Self-citation
Cardiovascular Disease in Type 2 Diabetes Mellitus
Mooradian, A. D. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.1.33 · Cited by 158
Statin Therapy in Acute Coronary Syndromes
Sposito, A. C., & Chapman, M. J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000032033.39301.6a · Cited by 157
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study
Heart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(10)62174-5 · Cited by 159
Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis
Custodero, C., Mankowski, R. T., Lee, S. A., Chen, Z., Wu, S. S., Manini, T. M., Hincapie-Echeverri, J., Sabbà, C., Beavers, D. P., Cauley, J. A., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.004 · Cited by 169
Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction
Anderson, T. J. (2003) · Heart Failure Reviews · doi:10.1023/a:1022199021949 · Cited by 158
Early vascular benefits of statin therapy
Tsiara, S., Elisaf, M., & Mikhailidis, D. P. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002225 · Cited by 157
Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin
González, A. S., Bellido, D., Soto, M. B., Pértega-Díaz, S., Olmos, M. Á. M., & Vidal, O. (2006) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602384 · Cited by 158
C-reactive protein: From innocent bystander to pivotal mediator of atherosclerosis
Labarrere, C. A., & Zaloga, G. P. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.03.039 · Cited by 158
State of the Art Reviews: The Anti-Inflammatory Actions of Exercise Training
Flynn, M. G., McFarlin, B. K., & Markofski, M. M. (2007) · American Journal of Lifestyle Medicine · doi:10.1177/1559827607300283 · Cited by 154
Evaluating the Clinical Utility of a Biomarker
Pletcher, M. J., & Pignone, M. P. (2011) · Circulation · doi:10.1161/circulationaha.110.943860 · Cited by 172
The use of high-sensitivity assays for C-reactive protein in clinical practice
Musunuru, K., Kral, B. G., Blumenthal, R. S., Fuster, V., Campbell, C. Y., Gluckman, T. J., Lange, R. A., Topol, E. J., Willerson, J. T., Desai, M. Y., et al. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1322 · Cited by 160
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease
Roberts, W. L. (2004) · Circulation · doi:10.1161/01.cir.0000148986.52696.07 · Cited by 157
C-Reactive Protein — To Screen or Not to Screen?
Mosca, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejme020127 · Cited by 148
Matrix Metalloproteinases and Diabetic Vascular Complications
Kadoglou, N. P. E., Daskalopoulou, S. S., Perrea, D. N., & Liapis, C. D. (2005) · Angiology · doi:10.1177/000331970505600208 · Cited by 150
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts).
Backer, G. D., Ambrosio, G., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · PubMed · doi:10.1097/01.hjr.0000087913.96265.e2 · Cited by 153
Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease
Sadowitz, B. D., Maier, K. G., & Gahtan, V. (2010) · Vascular and Endovascular Surgery · doi:10.1177/1538574410362922 · Cited by 150
The JUPITER Trial
Ridker, P. M. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.868299 · Cited by 148
Self-citation
Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis
März, W., Genser, B., Drechsler, C., Krane, V., Grammer, T. B., Ritz, E., Stojaković, T., Scharnagl, H., Winkler, K., Holme, I., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09121010 · Cited by 146
Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients
John, S., Schneider, M. P., Delles, C., Jacobi, J., & Schmieder, R. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.06.027 · Cited by 145
Inflammation-Sensitive Plasma Proteins, Diabetes, and Mortality and Incidence of Myocardial Infarction and Stroke
Engström, G., Stavenow, L., Hedblad, B., Lind, P., Eriksson, K., Janzon, L., & Lindgärde, F. (2003) · Diabetes · doi:10.2337/diabetes.52.2.442 · Cited by 143
Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease
Rossi, E. M. C., Biasucci, L. M., Citterio, F., Pelliccioni, S., Monaco, C. G., Ginnetti, F., Angiolillo, D. J., Grieco, G., Liuzzo, G., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0702.104126 · Cited by 141
Increased carotid intima media thickness and cardiac biomarkers in HIV infected children
McComsey, G. A., O’Riordan, M., Hazen, S. L., El‐Bejjani, D., Bhatt, S., Brennan, M., Storer, N. J., Adell, J., Nakamoto, D., & Dogra, V. S. (2007) · AIDS · doi:10.1097/qad.0b013e328133f29c · Cited by 142
Statins and the Acute-Phase Response
Munford, R. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442609 · Cited by 142
Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-012-0002-3 · Cited by 141
The Value of C-Reactive Protein in Cardiovascular Risk Prediction
van der Meer, I. M., de Maat, M. P. M., Kiliaan, A. J., van der Kuip, D. A. M., Albert Hofman, D., & Witteman, J. C. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.11.1323 · Cited by 141
Pro-inflammatory cytokines in acute coronary syndromes: From bench to bedside
Tousoulis, D., Antoniades, C., Koumallos, N., & Stefanadis, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.04.003 · Cited by 139
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139
Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors
Remaley, A. T., Rifai, N., & Warnick, G. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00027-5 · Cited by 139
Self-citation
Vascular inflammation and low‐density lipoproteins: is cholesterol the link? A lesson from the clinical trials
Catapano, A. L., Pirillo, A., & Norata, G. D. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13805 · Cited by 138
Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis
Horn, S. R., Long, M. M., Nelson, B. W., Allen, N. B., Fisher, P. A., & Byrne, M. L. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.016 · Cited by 129
Kidney Dysfunction, Inflammation, and Coronary Events
Knight, E. L., Rimm, E. B., Pai, J. K., Rexrode, K. M., Cannuscio, C. C., Manson, J. E., Stampfer, M. J., & Curhan, G. C. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000128966.55133.69 · Cited by 140
Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis
Libby, P. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800099-jlr200 · Cited by 137
Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis
Doornum, S. V., McColl, G., & Wicks, I. P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018333 · Cited by 138
Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators
Brigadeau, F., Kouakam, C., Klug, D., Marquié, C., Duhamel, A., Mizon-Gérard, F., Lacroix, D., & Kacet, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi726 · Cited by 136
Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial
Buettner, C., Nir, R., Bertisch, S. M., Bernstein, C. A., Schain, A. J., Mittleman, M. A., & Burstein, R. (2015) · Annals of Neurology · doi:10.1002/ana.24534 · Cited by 136
Need to Test the Arterial Inflammation Hypothesis
Bhatt, D. L., & Topol, E. J. (2002) · Circulation · doi:10.1161/01.cir.0000021112.29409.a2 · Cited by 136
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice
Jahagirdar, R., Zhang, H., Azhar, S., Tobin, J., Attwell, S., Yu, R., Wu, J., McLure, K. G., Hansen, H. C., Wagner, G. S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.008 · Cited by 134
C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease—Advancing toward Precision Medicine
Amezcua-Castillo, E., González‐Pacheco, H., Martín, A. S.-S., Méndez-Ocampo, P., Gutiérrez-Moctezuma, I., Massó, F., Sierra‐Lara, D., Springall, R., Rodrı́guez, E., Arias‐Mendoza, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092444 · Cited by 152
Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment
Saleh, Y., Abdelkarim, O., Herzallah, K., & Abela, G. S. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09968-2 · Cited by 132
Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients
Ferramosca, E., Burke, S. K., Chasan-Taber, S., Ratti, C., Chertow, G. M., & Raggi, P. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.023 · Cited by 132
The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes
Dandona, P., Aljada, A., Chaudhuri, A., & Bandyopadhyay, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030178 · Cited by 129
Statins and the endothelium
Ii, M., & Losordo, D. W. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.06.012 · Cited by 132
Monitoring of inflammation in patients on dialysis: forewarned is forearmed
Meuwese, C. L., Stenvinkel, P., Dekker, F. W., & Carrero, J. J. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.2 · Cited by 129
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.
Charles-Schoeman, C., González-Gay, M., Kaplan, I., Boy, M., Geier, J., Luo, Z., Zuckerman, A. L., & Riese, R. (2016) · Seminars in Arthritis & Rheumatism · doi:10.1016/j.semarthrit.2016.03.004 · Cited by 128
Approach to lipoprotein management in 2001 National Cholesterol Guidelines
Grundy, S. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02631-0 · Cited by 128
Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity
Ridker, P. M. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00372.x · Cited by 132
Self-citation
Elevated Levels of High-Sensitivity C-Reactive Protein and Serum Amyloid-A Late After Kawasaki Disease
Mitani, Y., Sawada, H., Hayakawa, H., Aoki, K., Ohashi, H., Matsumura, M., Kuroe, K., Shimpo, H., Nakano, M., & Komada, Y. (2004) · Circulation · doi:10.1161/01.cir.0000151311.38708.29 · Cited by 128
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Statins in liver disease
Argo, C. K., Loria, P., Caldwell, S. H., & Lonardo, A. (2008) · Hepatology · doi:10.1002/hep.22402 · Cited by 132
Early Withdrawal of Statin Therapy in Patients With Non–ST-Segment Elevation Myocardial Infarction National Registry of Myocardial Infarction
Spencer, F. A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2162 · Cited by 125
Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein
Ridker, P. M., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Khurmi, N. S., Köenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.072 · Cited by 125
Self-citation
Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles
Wang, T.-D., Chen, W.-J., Lin, J.-W., Cheng, C.-C., Chen, M.-F., & Lee, Y.-T. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00296-x · Cited by 125
Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia
Ketteler, M., Wanner, C., Metzger, T., Bongartz, P., Westenfeld, R., Gladziwa, U., Schurgers, L. J., Vermeer, C., Jahnen‐Dechent, W., & Floege, J. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.21.x · Cited by 125
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)—TIMI 22 trial
Cannon, C. P., McCabe, C. H., Belder, R., Breen, J. D., & Braunwald, E. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02201-4 · Cited by 122
Acute coronary syndrome without ST elevation: implementation of new guidelines
Hamm, C. W., Bertrand, M. E., & D, E. B. M. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06585-0 · Cited by 125
Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein
Sager, P. T., Melani, L., Lipka, L., Strony, J. T., Yang, B., Suresh, R., & Veltri, E. P. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.048 · Cited by 125
Oxidative stress and endothelial dysfunction: Therapeutic implications
Gori, T., & Münzel, T. F. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.543920 · Cited by 126
Statins: Potential new indications in inflammatory conditions
Endres, M. (2006) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2006.01.005 · Cited by 123
Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-Lowering Mechanisms in Patients With Coronary Heart Disease
Zhao, S. P., Liu, L., Cheng, Y. C., Shishehbor, M. H., Liu, M. H., Peng, D. Q., & Li, Y. L. (2004) · Circulation · doi:10.1161/01.cir.0000139985.81163.ce · Cited by 123
High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities
Fonseca, F. A. H., & Izar, M. C. D. O. (2016) · Clinics · doi:10.6061/clinics/2016(04)11 · Cited by 123
Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome
Mani, P., Puri, R., Schwartz, G. G., Nissen, S. E., Shao, M., Kastelein, J. J. P., Menon, V., Lincoff, A. M., & Nicholls, S. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0179 · Cited by 128
Statins: Could an old friend help in the fight against COVID‐19?
Rodrigues-Díez, R. R., Tejera‐Muñoz, A., Márquez‐Expósito, L., Rayego‐Mateos, S., Santos‐Sanchez, L., Marchant, V. A., Tejedor-Santamaria, L., Ramos, A. M., Ortíz, A., Egido, J., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15166 · Cited by 121
Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein
Busch, M., Franke, S., Müller, A., Wolf, M., Gerth, J., Ott, U., Niwa, T., & Stein, G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00736.x · Cited by 121
Perioperative stroke
Vlisides, P. E., & Mashour, G. A. (2015) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-015-0494-9 · Cited by 126
Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia
Rosenson, R. S. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.4.495 · Cited by 123
The Effects of Atorvastatin on Endothelial Function in Diabetic Patients and Subjects at Risk for Type 2 Diabetes
Economides, P. A., Caselli, A., Tiani, E., Khaodhiar, L., Horton, E. S., & Veves, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031116 · Cited by 120
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel, T. N., Shishehbor, M. H., & Bhatt, D. L. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl445 · Cited by 119
Statins: panacea for sepsis?
Terblanche, M., Almog, Y., Rosenson, R. S., Smith, T. S., & Hackam, D. G. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70439-x · Cited by 118
Erythrocyte Sedimentation Rate, an Independent Predictor of Coronary Heart Disease in Men and Women: The Reykjavik Study
Andresdottir, M. B. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg222 · Cited by 118
WBC Count and the Risk of Cancer Mortality in a National Sample of U.S. Adults: Results from the Second National Health and Nutrition Examination Survey Mortality Study
Erlinger, T. P., Muntner, P., & Helzlsouer, K. J. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1052.13.6 · Cited by 118
C-Reactive Protein: Clinical and Epidemiological Perspectives
Salazar, J., Martínez, M. S., Chávez, M., Toledo, A., Añez, R., Torres, Y., Apruzzese, V., Silva, C., Rojas, J., & Bermúdez, V. (2014) · Cardiology Research and Practice · doi:10.1155/2014/605810 · Cited by 117

Authors: Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
Affiliations: Brigham and Women's Hospital (US)
University of North Texas Health Science Center (US)
Wilford Hall Ambulatory Surgical Center (US)
ORCID: Ridker, Paul M.
Rifai, Nader
Weis, Stephen E.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-06-28
Volume: 344
Issue: 26
Pages: 1959-1965
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200106283442601
OpenAlex: W2316243284
Cited by: 1,557
References: 27
Citations by year: 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
FWCI: 158.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Doris Duke Charitable Foundation
American Heart Association
Fondation Leducq
National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
MeSH terms: Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks